Sentiment-Signal
6,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Unternehmen & Branche
| Name | Maze Therapeutics, Inc. |
|---|---|
| Ticker | MAZE |
| CIK | 0001842295 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,41 Mrd. USD |
| Beta | 5,16 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -131,120,000 | -3.05 | 397,127,000 | 354,966,000 | |
| 2025-09-30 | 10-Q | -30,087,000 | -0.66 | 422,058,000 | 379,436,000 | |
| 2025-06-30 | 10-Q | 0 | -33,679,000 | -0.77 | 303,519,000 | 262,238,000 |
| 2025-03-31 | 10-Q | -32,786,000 | -1.15 | 332,840,000 | 292,068,000 | |
| 2024-12-31 | 10-K | 167,500,000 | 52,231,000 | 1.25 | 240,542,000 | -311,183,000 |
| 2024-09-30 | 10-Q | 2,500,000 | -24,752,000 | -10.25 | ||
| 2024-06-30 | 10-Q | 165,000,000 | 139,056,000 | 3.22 | ||
| 2024-03-31 | 10-Q | -32,494,000 | -13.91 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -3,348 | 30.06 | -100,635.86 | -29,9% | |
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -11,352 | 29.24 | -331,948.37 | -98,6% | |
| 2026-04-01 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -300 | 31.07 | -9,320.01 | -2,8% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -3,795 | 49.32 | -187,168.64 | -55,6% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -6,161 | 48.20 | -296,976.83 | -88,2% | |
| 2026-03-20 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -5,044 | 50.02 | -252,293.82 | -75,0% | |
| 2026-03-10 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -29,652 | 50.45 | -1,495,807.00 | -444,4% | |
| 2026-03-10 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -348 | 51.02 | -17,753.22 | -5,3% | |
| 2026-03-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -3,700 | 45.47 | -168,236.78 | -50,0% | |
| 2026-03-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -1,300 | 44.44 | -57,773.82 | -17,2% | |
| 2026-02-27 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3,761 | 45.72 | -171,967.21 | -51,1% | |
| 2026-02-27 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3,739 | 45.13 | -168,756.03 | -50,1% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -5,936 | 46.37 | -275,271.32 | -81,8% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -600 | 44.21 | -26,523.00 | -7,9% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -100 | 47.23 | -4,723.00 | -1,4% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -736 | 46.63 | -34,321.37 | -10,2% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -200 | 44.15 | -8,830.00 | -2,6% | |
| 2026-02-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -4,064 | 46.03 | -187,067.95 | -55,6% | |
| 2026-02-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -8,364 | 45.89 | -383,816.43 | -114,0% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -3,500 | 44.04 | -154,146.65 | -45,8% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -1,200 | 43.18 | -51,821.28 | -15,4% | |
| 2026-01-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -2,800 | 45.01 | -126,022.40 | -37,4% | |
| 2026-01-22 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -5,000 | 45.52 | -227,612.00 | -67,6% | |
| 2026-01-07 | Sohn Catherine A. | Director | Open Market Sale | -26,920 | 39.11 | -1,052,784.67 | -312,8% | |
| 2026-01-07 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -25,156 | 40.20 | -1,011,298.87 | -300,5% | |
| 2026-01-06 | Sohn Catherine A. | Director | Open Market Sale | -2,493 | 38.62 | -96,269.69 | -28,6% | |
| 2026-01-05 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -412 | 40.00 | -16,480.00 | -4,9% | |
| 2026-01-02 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -4,432 | 40.43 | -179,187.53 | -53,2% | |
| 2026-01-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -2,595 | 39.57 | -102,681.30 | -30,5% | |
| 2026-01-02 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -2,405 | 38.70 | -93,072.30 | -27,7% | |
| 2025-12-30 | Dandekar Atul | Officer, CSBO | Open Market Sale | -100 | 40.36 | -4,036.00 | -1,2% | |
| 2025-12-30 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -5,000 | 40.08 | -200,407.00 | -59,5% | |
| 2025-12-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -6,035 | 41.13 | -248,211.10 | -73,7% | |
| 2025-12-29 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -27,800 | 40.34 | -1,121,424.20 | -333,2% | |
| 2025-12-29 | Bernstein Harold | Officer, President, R&D & CMO | Open Market Sale | -17,200 | 40.93 | -703,930.64 | -209,1% | |
| 2025-12-29 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -9,400 | 40.54 | -381,071.30 | -113,2% | |
| 2025-12-29 | Bachrodt Amy | Officer, SVP, Finance | Open Market Sale | -600 | 41.16 | -24,694.98 | -7,3% | |
| 2025-12-29 | Dandekar Atul | Officer, CSBO | Open Market Sale | -66,365 | 40.51 | -2,688,552.33 | -798,8% | |
| 2025-09-15 | SCHELLER RICHARD H | Director | Open Market Sale | -20,744 | 22.37 | -464,034.98 | -137,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.